Navigation Links
Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
Date:8/13/2012

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 9:10 a.m. EDT on Wednesday, August 15, 2012, at the Le Parker Meridien Hotel in New York City. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its Phase 2 clinical development programs for multiple sclerosis and inflammatory bowel disease with RPC1063.

About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information - driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a best-in-class S1P1 small molecule agonist candidate for autoimmune indications. Receptos' expertise in S1P1 biology has been informed by the company's high resolution protein crystal structure of the S1P1 receptor, published in Science earlier this year. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271
Ian.stone@russopartnersllc.com
David.schull@russopartnersllc.com 


'/>"/>
SOURCE Receptos Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
2. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
3. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
4. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
6. Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference
7. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
8. Cepheid to Webcast Upcoming Financial Presentations
9. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. STAAR Surgical To Present At The 32nd Annual Canaccord Growth Conference
11. Solta Medical to Present at the 32nd Annual Canaccord Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017  BDI Group subsidiary Pathway ... support services organization serving specialty pharmacies, home infusion ... of four significant, value-added member programs designed to ... manage reimbursement and improve access and affordability for ... Pathway ...
(Date:7/10/2017)... 10, 2017 Locus Biosciences Inc. today announced ... the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the ... Chinese Internet services provider, and joined by the North ... disease product programs targeting antibiotic resistant infections and other ... by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the Buffalo and ... was born in Toledo, Ohio. He attended Woodward High School. He earned an ... a brilliant woman with a caring heart named Tiina, who is a hospice nurse. ...
(Date:7/18/2017)... ... 18, 2017 , ... Cognition Corporation , a software ... sessions of its “From the Helm” Webinar Series. , These sessions will ... Cognition’s CEO, the half-hour public webinars will take an in-depth look at applying ...
(Date:7/18/2017)... Calif. (PRWEB) , ... July 18, 2017 , ... The results of an international clinical ... a drug therapy for a severe type of muscular dystrophy holds promise for a subgroup ... , Craig McDonald and colleagues at 53 study sites in 18 countries describe ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, Wash., knows ... menopause, I have frequent hot flashes, and I suffer from anxiety and vertigo on ... keep cool while out and about." INSTA-FAN meets that need. , This device enables ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... Heritage Woods ... from 11 a.m. to 12:30 p.m. on Aug. 15. , The community, which is ... including those on Medicaid, who need some help to maintain their independence. , The ...
Breaking Medicine News(10 mins):